Clopidogrel
Product Images NDC 55648-314

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 55648-314). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Wockhardt Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Clopidogtabs M Figure 01)

Chemical structure of Clopidogrel shown with its molecular arrangement including a thienopyridine ring, a chlorine-substituted phenyl group, and a carboxylate ester moiety associated with sulfuric acid (H2SO4).*

FDA Label Image

Figure 1 (Clopidogtabs M Figure 02)

A horizontal bar graph showing the effect of co-administered proton pump inhibitors (PPIs) on the active metabolite AUC of Clopidogrel. The PPIs listed are Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg, with corresponding mean values and 90% confidence intervals indicating changes relative to Clopidogrel administered alone.*

FDA Label Image

Figure 2 (Clopidogtabs M Figure 03)

A line graph comparing the cumulative event rate (%) of cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up between Clopidogrel plus aspirin and placebo plus aspirin. The graph shows a consistently lower event rate for Clopidogrel plus aspirin compared to placebo plus aspirin.*

FDA Label Image

Figure 3 (Clopidogtabs M Figure 04)

A chart presenting hazard ratios with 95% confidence intervals comparing Clopidogrel (plus aspirin) versus placebo (plus aspirin) across various baseline patient characteristics and concomitant medication/therapy groups. The graph shows subgroup analyses including diagnosis, age, gender, race, cardiac enzyme elevation, diabetes, prior myocardial infarction and stroke, and use of medications such as Heparin, aspirin, beta-blockers, ACE inhibitors, and lipid-lowering agents.*

FDA Label Image

Figure 4 (Clopidogtabs M Figure 05)

A line graph comparing the percentage of deaths before first discharge over 28 days between a Placebo group and a Clopidogrel group. The vertical axis shows the percentage dead, and the horizontal axis shows days since randomization. The graph indicates a 7% proportional risk reduction in deaths for the Clopidogrel group compared to Placebo, with death counts and percentages noted for both groups.*

FDA Label Image

Figure 5 (Clopidogtabs M Figure 06)

A Kaplan-Meier curve comparing the percentage of patients with death, reinfarction, or stroke before first discharge over 28 days for Clopidogrel versus placebo groups. The graph shows a lower event rate for Clopidogrel (9.2%) compared to placebo (10.1%) with a 9% proportional risk reduction noted.*

FDA Label Image

Figure 6 (Clopidogtabs M Figure 07)

A forest plot chart comparing Clopidogrel versus placebo across various baseline categorizations, including sex, age groups, hours since onset, systolic blood pressure categories, heart rate, fibrinolytic agent use, prognostic index, and metoprolol allocation. The chart displays event percentages, odds ratios with 95% confidence intervals, and heterogeneity tests for each subgroup.*

FDA Label Image

Figure 7 (Clopidogtabs M Figure 08)

A forest plot chart showing odds ratios and confidence intervals comparing Clopidogrel and placebo across different categorizations: Killip class, previous myocardial infarction (MI), and infarct location. The plot includes event percentages for Clopidogrel and placebo groups, with statistical heterogeneity tests and proportional reduction data presented.*

FDA Label Image

Figure 8 (Clopidogtabs M Figure 09)

A line graph showing cumulative event rates (%) of fatal or non-fatal vascular events over 36 months of follow-up. The graph compares outcomes for Aspirin and Clopidogrel, with cumulative event rates on the vertical axis and months on the horizontal axis. A p-value of 0.045 is indicated on the graph.*

FDA Label Image

Label (Clopidogtabs M Figure 10)

Clopidogrel Tablets USP 75 mg label from Wockhardt Limited displays dosage strength and tablet count. The label includes dosing instructions referencing package insert, storage temperature guidelines (20°-25°C), and indicates the product contains 90 tablets. It shows distribution and manufacturing details with a barcode and the Wockhardt logo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.